Genyro — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Genyro is a private, pre-revenue platform company founded in 2019 with a mission to enable the predictable engineering of biology. Its proprietary DNA assembly technology, developed from academic research at Caltech, seeks to overcome the sequence-dependent limitations of traditional DNA synthesis and assembly, allowing for the construction of any designed sequence. Led by a team with deep expertise in synthetic biology, genomics, and AI, the company is positioning itself as a potential enabler for next-generation biomanufacturing, therapeutics, and other bio-based industries. Its success hinges on scaling its platform and demonstrating its utility in high-value applications.

Genetics & GenomicsAI / Machine Learning

Technology Platform

Sidewinder / 'page-number logic' DNA assembly platform that uses barcodes to guide precise, sequence-agnostic construction of DNA, enabling the building of any designed sequence.

Opportunities

The platform addresses a fundamental bottleneck in synthetic biology, positioning Genyro to enable advancements across cell/gene therapy, biomanufacturing, and basic research.

If scalable, it could become a critical infrastructure provider for the growing bioeconomy, capturing value across multiple industries.

Risk Factors

Key risks include the challenge of scaling a novel academic technology to industrial reliability and cost, competition from established DNA synthesis and foundry companies, and the difficulty of driving adoption in a conservative biopharma market.

As a pre-revenue company, it remains highly dependent on venture funding.

Competitive Landscape

Genyro competes in the DNA synthesis and assembly space with large-scale providers like Twist Bioscience and Ginkgo Bioworks, as well as other startups developing novel assembly methods. Its differentiation hinges on its claimed sequence-agnostic assembly capability, which, if proven, could overcome limitations of current technologies.

More companies in Synthetic Biology →More companies in United States →